Environmental

Low Direct Environmental Footprint: Aurinia Pharmaceuticals operates as a specialty biopharmaceutical company with limited manufacturing infrastructure, resulting in a relatively low direct carbon and resource footprint compared to large-scale pharmaceutical peers.

Product Lifecycle and Waste Management: The company outsources most manufacturing, which reduces its direct environmental impact but requires oversight of third-party suppliers’ environmental practices to mitigate supply chain risks.

Regulatory Compliance: Aurinia reports compliance with applicable environmental regulations and has not disclosed any material environmental violations or penalties in recent filings.

Aurinia’s environmental risk profile is favorable due to its asset-light model and strong regulatory compliance. The main exposure is indirect, through third-party suppliers, but no material issues have been reported.

Social

Workforce Diversity and Inclusion: Aurinia discloses workforce diversity metrics and has implemented policies to promote inclusion, though its small size limits the scale of these initiatives compared to larger peers.

Product Safety and Patient Access: The company’s lead product, LUPKYNIS, addresses a significant unmet medical need in lupus nephritis, with robust clinical data supporting safety and efficacy. Ongoing post-marketing surveillance and patient support programs are in place.

Community Engagement and Stakeholder Relations: Aurinia engages with patient advocacy groups and healthcare stakeholders, but its community investment and outreach remain modest relative to industry leaders.

Aurinia demonstrates a commitment to patient safety and workforce inclusion, but its social impact is constrained by its scale. Continued focus on patient access and stakeholder engagement is evident, though broader community impact is limited.

Governance

Board Independence and Diversity: Aurinia’s board is majority independent and includes diverse representation, aligning with best practices for governance in the sector.

Executive Compensation Alignment: Stock-based compensation is moderate relative to revenue (6.4%), indicating reasonable alignment with shareholder interests and sector norms.

Risk Management and Compliance: The company maintains robust risk oversight, including compliance with regulatory requirements and internal controls, with no recent material governance controversies reported.

Aurinia’s governance structure is sound, with independent oversight and reasonable executive pay practices. The company’s risk management and compliance frameworks are appropriate for its size and complexity.

Overall Score

Aurinia Pharmaceuticals demonstrates strong environmental performance due to its asset-light model and regulatory compliance. Social and governance practices are solid but not industry-leading, reflecting the company’s smaller scale. Overall, ESG risks are well managed, with no material controversies or deficiencies relative to peers.